Story Highlight
– UK recognized for strong pharmacovigilance and safety monitoring.
– Digitization and AI enhance Yellow Card reporting efficiency.
– New Health Data Research Service to boost safety capabilities.
– Real-world data enables proactive drug safety analyses.
– UK aims for near real-time pharmacovigilance systems.
Full Story
As the landscape of healthcare evolves with increasingly sophisticated medicines and medical technologies, there emerge significant opportunities to enhance systems for monitoring safety. The United Kingdom has a longstanding reputation for excellence in pharmacovigilance, primarily facilitated by the Medicines and Healthcare products Regulatory Agency (MHRA) through its well-known Yellow Card scheme, which remains crucial for the early detection of safety issues associated with medication.
The intricacies of modern medical products are matched by the rapidity with which they reach patients and the diverse populations they serve. The COVID-19 pandemic has underscored the necessity for a nimble and responsive safety monitoring system. Professor Aziz Sheikh articulated this in his recent blog contribution, noting the strides made during the pandemic, including the digitisation of the Yellow Card reporting platform and the integration of artificial intelligence to manage a vast influx of reports. This combination of enhanced passive surveillance and more active monitoring through national usage data and anonymised electronic health records has proven effective in overseeing vaccine safety.
Looking ahead, the anticipated launch of the Health Data Research Service represents a pivotal moment to build upon these advancements. By applying the successful protocols and technologies developed during the pandemic to other pharmaceuticals and medical products, the UK can amplify its status as a leader in real-time safety surveillance, thereby bolstering patient protection.
Professor Sir Aziz Sheikh, who serves as Pro-Vice-Chancellor and Head of the Nuffield Department of Primary Care Health Sciences at the University of Oxford, is amongst the foremost experts in primary care and public health. His insights have significantly contributed to enhancing the UK’s capabilities in drug safety and evidence-based health policies.
While the existing pharmacovigilance frameworks have provided invaluable support, they can still be classified as predominantly passive. The shift away from traditional methods—such as relying on healthcare professionals to manually submit Yellow Card reports—has led to the emergence of more advanced reporting systems. However, the voluntary nature of reporting remains a substantial drawback, prolonging the process of identifying and assessing safety signals. Professor Sheikh argues for a more active and systematic approach to identifying medication-related harm, enabling swift intervention to mitigate risks.
The digitisation of the National Health Service (NHS) has been a prolonged but ultimately fruitful endeavour, now culminating in a comprehensive system spanning the UK population. This digitised framework permits the integration of real-world data across the entire continuum of care, using unique identifiers such as NHS numbers. Such advancements lay a strong foundation for the next generation of pharmacovigilance systems capable of conducting routine analyses to understand the incidence of known adverse events. These systems can identify vulnerable sub-populations predisposed to medication risks and enable detailed epidemiological investigations into adverse events reported through the Yellow Card scheme and other channels.
One notable assessment conducted during this optimisation of pharmacovigilance related to varenicline, a widely used smoking cessation aid that was initially linked to heightened cardiovascular and neuropsychiatric risks. After small-scale studies suggested the need for caution, the US Food and Drug Administration (FDA) issued a black box warning. However, a large-scale retrospective cohort study in the UK leveraging the QRisk database did not corroborate the heightened risk, thereby supporting the continued use of varenicline.
The FDA Sentinel System, which encompasses one of the largest databases in the world, is a model of success in the realm of electronic health records, conducting federated safety analyses across approximately 170 million patients across various healthcare institutions in the United States. While the UK may not match the scale of the FDA’s database, its population of approximately 68 million offers a unique opportunity to conduct robust safety analyses capable of detecting most rare safety signals.
One advantage the UK holds is the capacity to perform safety evaluations on a national population level, minimising biases and enhancing the applicability of the findings. As authorities establish comprehensive data pipelines and standardise the processes for data curation and analysis, there is potential for automating common analyses. Such automation would create a system that continuously evaluates drug-related adverse events, operating “in the background” to maintain vigilance over patient safety.
Although these aspirations may appear ambitious, substantial progress on critical components has been made in recent years. This includes the systematic implementation of unique NHS numbers, advancements in cloud technology for data storage, improved methods for data linkage, and the groundwork laid during the pandemic to ensure the UK can efficiently embark on high-quality vaccine and drug safety initiatives involving the entire population.
With the imminent rollout of the Health Data Research Service, bolstered by substantial support from the UK Government, there lies an unparalleled opportunity to leverage the country’s exemplary strengths in pharmacovigilance. The goal is to create a near-real-time, population-wide capability that supports the secure and effective application of drugs, ultimately propelling advancements in public health outcomes.
Our Thoughts
The article highlights the advancements in pharmacovigilance in the UK, particularly during the COVID-19 pandemic. However, it emphasizes the need for a more proactive approach to safety monitoring rather than relying on passive reporting systems. Key lessons include the necessity for a systematic effort to identify medication-related harms, implying a breach of the Health and Safety at Work Act 1974, which requires adequate systems to manage health and safety risks.
To prevent similar incidents, regulatory frameworks like the Medicines and Medical Devices Act 2021 could be utilized to enforce mandatory reporting of adverse events, addressing the current voluntary nature that hinders timely signal detection. Incorporating advanced technologies, such as AI for real-time data analysis, could enhance early identification of risks and improve patient safety.
By leveraging the whole population data from the NHS, establishing automated safety analyses, and fostering a culture of proactive risk management, the UK could significantly improve its pharmacovigilance capabilities and prevent future adverse health outcomes associated with medications.
